Info@ThinkPinkRocks.com

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.

See more here:
Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Share

Leave a Reply

Solve : *
1 + 5 =